Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Excipial Hydrolotion is a moisturizing oil-in-water (O/W) emulsion designed to hydrate and protect the skin barrier. In clinical settings, such as trials conducted by the University of Bern, it is utilized as an institutional standard-of-care topical treatment for the prevention and management of radiation dermatitis in patients undergoing radiotherapy, particularly for breast cancer. The formulation typically contains urea (often at a 2% concentration) and lipids, functioning as both an emollient and a humectant. It works by increasing the water-binding capacity of the stratum corneum and restoring the lipid film on the skin surface, which helps mitigate the dryness and irritation associated with radiation-induced skin damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Excipial Hydrolotion.